Adriamisin Uygulamasının Sıçan Kalp Dokusunda Nesfatin-1 İmmünreaktivitesi Üzerine Etkileri

Amaç: Adriamisin birçok solid tümörün ve hematolojik malignitenin tedavisinde kullanılan geniş spektrumlu bir kanser ilacıdır. Adriamisin kullanımının ana yan etkisinin kalp yetmezliği ve kardiyomyopati olduğu bilinmektedir. Yapılan çalışmalar adriamisin kardiyotoksisitesinin patogenezinde oksidatif stresin önemli bir rol oynadığını göstermektedir. Nesfatin-1 diyabet, obezite, anoreksia nervoza, psikiyatrik bozukluklar ve nörojenik hastalıklar ile yakından ilişki göstermektedir. Nesfatin-1’in miyokardiyal performansı direk olarak etkilediği ve kalp kasını iskemi reperfüzyon hasarından koruduğu bildirilmiştir. Gereç ve Yöntem: Çalışmamızda erişkin Wistar albino erkek sıçanlar kullanıldı. Deney hayvanları her grupta 6 hayvan olmak üzere 2 gruba ayrıldı. Kontrol grubuna deney süresi olan 14 gün boyunca herhangi bir işlem yapılmadı. Adriamisin grubuna ise10 mg/kg/tek doz adriamisin intraperitoneal olarak verildi. Deney sonunda sıçanlar anestezi altında dekapite edilerek kalp dokuları çıkarıldı. Rutin protokoller ile dokular parafin bloklara gömüldü. Kesitlere Nesfatin-1 immünreaktivitesi için avidin-biotin-peroksidaz yöntemi uygulandı. Sitoplazmik immün boyanmanın yaygınlığı 0’dan +3’e kadar sayı ile semi-kantitatif olarak skorlandı. Bulgular: Nesfatin-1 immünreaktivitesi, kontrol grubunda kalp dokusunda miyositlerde +3 yaygınlığında izlendi. Kontrol grubu ile karşılaştırıldığında nesfatin-1 immünreaktivitesinde adriamisin grubunda miyositlerde belirgin bir azalma vardı ve +1 yaygınlığında tespit edildi. Sonuç: Sıçan kalp dokusunda nesfatin-1 salınımın olduğu, deneysel adriamisin uygulanmasının sıçan kalp dokusunda nesaftin-1 immünreaktivitesini azalttığı, bunun da adriamisine bağlı miyosit hasarı ve/veya kaybına bağlı olabileceği kanaatindeyiz.

The Affects of Adriamycin Implementation to The Immunreactivity of Nesfatin-1 at Rat Heart Tissue

Objective: Adriamycin is a broad-spectrum anticancer drug that is used at various type of solid tumors and hematologic malignancies. The main side effects of adriamycin are heart failure and cardiomyopathy. Studies suggests that, oxidative stress plays an important role in the pathogenesis of adriamycin cardiotoxicity. Nesfatin-1 is closely associated with diabetes, obesity, anorexia nervosa, psychiatric disorders, and neurogenic diseases. It has been reported that Nesfatin -1 directly affects the myocardial performance and protects the myocardium from ischemia reperfusion injury. Material and Method In this study Wistar albino rats were used. Rats were divided into 2 groups. No application was made to control group at 14 days. To adriamycin group, 10mg/kg single dose adriamycin was injected intraperitoneally. Finally rats were decapitated and heart tissues were removed. With routine procedures, tissues were embedded in paraphine blockes. For nesfatin-1 immunreactivity ‘‘avidin-biotin-peroxidase’’ method was applied. Results In control group was observed at +3 diffusiveness in myocytes at heart tissue. In comparison with control group, nesfatin-1 immunoreactivity showed significant decrease at adriamycin group and was at +1 diffusiveness. Conclusion: As a result, rat heart tissue releases nesfatin-1, experimental implementation of adriamycin reduces nesfatin-1 immunoreactivity in rat heart tissue, and this decrease depends on myocardial damage / loss due to adriamycin.

Kaynakça

1. 2. 3. 4. 5. 6. 7. Cui J, Li C, Guo W, et al. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy. J Control Release 2007; 118: 204-15. Yen HC, Oberley TD, Vichitbandha S, Ho YS, St Clair DK. The protective role of manganese superoxide dismutase against adriamycin-induced acute cardiac toxicity in transgenic mice. J Clin Invest 1996; 98: 1253-60. Quiles JL, Huertas JR, Battino M, Mataix J, Ramırez-Tortosa MC. Antioxidant nutrients and adriamycin toxicity. Toxicology 2002; 180: 79-95. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999; 51: 691–743. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracy-clines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185-229. Wang G, Zhang J, Liu L, Sharma S, Dong Q. Quercetin potentiates doxorubicin mediated antitumor effects against liver cancer through p53/Bcl-xl. PLoS ONE 2012; 7: 5176. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxid Redox Signal 2001; 3: 135-45. 8. 9. 10. 11. 12. 13. 14. Olson RD, Mushlin PS. Doxorubicin cardiotoxicity, analysis of prevailing hypothesis. FASEB J 1990; 4: 3076-86. Rabelo E, DE Angelis K, Bock P, et al. Baroreflex sensitivity and oxidative stres in adriamycin induced heart failure. Hypertension 2001; 38: 576-80. Zhang YW, Shi J, Li YJ, Wei L. Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp (Warsz) 2009; 57: 435-45. Mantawy EM, El-Bakly WM, Esmat A, Badr AM, El- Demerdash E. Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Eur J Pharmacol 2014; 728: 107- 18. Dai H, Li X, He T, et al. Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides 2013; 46: 167-71. Oh-I S, Shimizu H, Satoh T, et al. Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 2006; 443: 709-12. Su Y, Zhang J, Tang Y, Bi F, Liu JN. The novel function of nesfatin-1: anti-hyperglycemia. Biochem Biophys Res Commun 2010; 391: 1039-42. 15. 16. 17. 18. 19. 20. 21. 22. 23. 24. 25. 26. Elmquist JK, Coppari R, Balthasar N, Ichinose M, Lowell BB. Identifying hypothalamic pathways controlling food intake, body weight, and glucose homeostasis. J Comp Neurol 2005; 493: 63-71. Mimee A, Smith PM, Ferguson AV. Nesfatin-1 influences the excitability of neurons in the nucleus of the solitary tract and regulates cardiovascular function. Am J Physiol Regul Integr Comp Physiol 2012; 302: 1297-304. Angelone T, Filice E, Pasqua T, et al. Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell Mol Life Sci 2013; 7: 495-509. Liu X. Protection of Pifithrin-α and Melatonin Against Doxorubicin-Induced ,Cardiotoxicity, Doctor’s Degree Thesis, East Tennessee State University Biomedical Science, United States 2003. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuweburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002; 62: 4592-8. Seifert CF, Nesser ME, Thompson DF. Dexrazoxane in the prevention of doxorubicin induced cardiotoxicity. Ann Pharmacother 1994; 28: 1063-72. Chachoua A, Hoschster H, Muggia FM. Doxorubicin. In Droz JP, Cvitkovic E, Armand JP, and Khoury S. (eds), Handbook of Chemotherapy in Clinical Oncology. Rhöne-Poulenc, Houston, 1988; 125-7. Tritton TR. Cell surface actions of adriamycin. Pharmac Ther 1991; 49: 293-309. Cummings J, Anderson L, Willmott N, Smyth JF. The molecular pharmacology of doxorubicin in vivo. Eur J Cancer 1991; 27: 532–5. Halliwell B. Free radicals and antioxidants: updating a personal view. Nutr Rev 2012; 70: 257-65. Myers C. The role of iron in doxorubicin-induced cardiomyopathy. Semin Oncol1998; 25: 10-4. Stengel A, Goebel M, Yakubov I, et al. Identification and characterization of nesfatin-1 immunoreactivity in endocrine celltypes of the rat gastric oxyntic mucosa. Endocrinology 2009; 150: 232-8. 27. 28. 29. 30. 31. 32. 33. 34. 35. 36. 37. Gonzalez R, Tiwari A, Unniappan S. Pancreatic cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem Biophys Res Commun 2009; 381: 643-8. Ramanjaneya M, Chen J, Brown JE, et al. Identification of nesfatin-1 in human and murine adipose tissue: a novel depot- specific adipokine with increased levels in obesity. Endocrinology 2010; 151: 3169-80. Garcia-Galiano D, Pineda R, Ilhan T, et al. Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology 2012; 153: 1959-71. Tsuchiya T, Shimizu H, Yamada M, et al. Fasting concentrations of Nesfatin-1 are negatively correlated with body mass index in non obese males. Clin Endocrinol (Oxf). 2010; 73: 484-90. Price TO, Samson WK, Niehoff ML, Banks WA. Permeability of the blood-brain barrier to a novel satiety molecule nesfatin- 1. Peptides 2007; 28: 2372–81. Brailoiu GC, Dun SL, Brailoiu E, et al. Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 2007; 148: 5088-94. Tang CH, Fu XJ, Xu XL, Wei XJ, Pan HS. The anti- inflammatory and anti-apoptotic effects of nesfatin-1 in the traumatic rat brain. Peptides 2012; 36: 39-45. Pałasz A, Krzystanek M, Worthington J, et al. Nesfatin-1, a unique regulatory neuropeptide of the brain. Neuropeptides 2012; 46: 105-12. Özsavci D, Ersahin M, Sener A, et al. The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats. Neurosurgery 2011; 68: 1699-708. Danelisen I. Metabolism of Retinol in Adriamycin-Induced Cardiomyopathy. Master’s Degree Thesis, University of Manitoba, Department of Physiology Faculty of Medicine, Canada, 2000. Singal PK, Deally CM, Weinberg LE. Subcellular effects of adriamycin in the heart: a concise review. J Mol Cell Cardiol 1987; 19: 817-28.

Kaynak Göster

879 428

Arşiv
Sayıdaki Diğer Makaleler

Adriamisin Uygulamasının Sıçan Kalp Dokusunda Nesfatin-1 İmmünreaktivitesi Üzerine Etkileri

Tuncay KULOĞLU, GÖKHAN ARTAŞ

Nöroloji Polikliniğine Baş Ağrısı Yakınması İle Başvuran Hastalarda Kraniyal Manyetik Rezonans Görüntüleme (MRG) Tetkiki İstenmeli midir?

HALİL AY, YUSUF İNANÇ, Tülay DOĞANTÜRK, Özcan KOCATÜRK

Nörofibromatozis Tip 1 ve Malign Periferik Sinir Kılıfı Tümörü

EMRAH AYTAÇ, Ayşegül AKYÜZ, Ceyla ATAÇ UÇAR, Cemile Sencer DEMİRCAN, Yonca TOPAL, Tahir Yoldaş KURTULUŞ

Testis Rüptüründe Konservatif Yaklaşım: Nadir Bir Olgu ve Tedavisi

MEHMET SARAÇ, ÜNAL BAKAL, Mehmet Ruhi ONUR, Tugay TATAR, AHMET KAZEZ

Comparison of Intra corporeal Knot-tying Suture and Hem-o-lok Clip for Closure of Appendix Stump in Laparoscopic Appendectomy: A Retrospective Study

Yılmaz POLAT, Erdem KNACI

Spondilokostal Dizostozis: Tipik Bulguları Olan Bir Yenidoğan Olgusu

Şah Mehmet İPEK, Nilüfer OKUR

Göğüs Duvarında Osteokondrom; 11 Olgu

MENDUH ORUÇ, Fatih MERETOĞLU, Ahmet ERBEY, Atalay ŞAHİN, SERDAR ONAT, REFİK ÜLKÜ

Özkıyım Girişimiyle Hastaneye Başvuran Hastaların Mizaç Özellikleri

OSMAN MERMİ, FARUK KILIÇ, MEHMET GÜRKAN GÜROK, Murat KULOĞLU, Murad ATMACA

Use of Uterine Balloon Tamponade For Managing Placental Invasion Anomalies: Retrospective Study

MEHMET ŞİMŞEK, Remzi ATILGAN, Uğur ORAK, SALİH BURÇİN KAVAK, Zehra Sema ÖZKAN, İsmail DEMİREL, HAKAN ARTAŞ, EKREM SAPMAZ

İyonize Radyasyon Uygulamasının Sıçan Karaciğer Dokularında Ghrelin Ekspresyonu Üzerine Etkileri

FİKRİ SELÇUK ŞİMŞEK, NEVİN KOCAMAN